Meadow Creek Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Meadow Creek Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-180	Closed	-$90K	–	1365
2019 Q2	$90K	Sell	180 -56	-24%	-$39.5K	﹤0.01%	1229
2019 Q1	$234K	Sell	236 -237	-50%	-$220K	﹤0.01%	958
2018 Q4	$410K	Sell	473 -225	-32%	-$209K	0.01%	706
2018 Q3	$721K	Buy	698 +48	+7%	+$46.9K	0.01%	581
2018 Q2	$598K	Buy	650 +16	+3%	+$17.2K	0.01%	581
2018 Q1	$618K	Buy	634 +535	+540%	+$488K	0.01%	563
2017 Q4	$45K	Sell	99 -66	-40%	-$24.4K	﹤0.01%	1283
2017 Q3	$68K	Sell	165 -21	-11%	-$7.92K	﹤0.01%	1217
2017 Q2	$65K	Sell	186 -60	-24%	-$23.1K	﹤0.01%	1204
2017 Q1	$127K	Hold	246	–	–	﹤0.01%	868
2016 Q4	$87K	Buy	+246	New	+$104K	﹤0.01%	967

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meadow Creek Investment Management's ATRA Position: Q3 2019 in Review

Meadow Creek Investment Management sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 180 shares — an estimated $90K sold.

Meadow Creek Investment Management first reported a position in ATRA in Q4 2016 and held it in 11 quarters. The position peaked at $721K in Q3 2018. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

Meadow Creek Investment Management reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
Meadow Creek Investment Management sold 180 Atara Biotherapeutics shares in Q3 2019, an estimated $90K.
Meadow Creek Investment Management first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 11 quarters.
Meadow Creek Investment Management's Atara Biotherapeutics position peaked at $721K in Q3 2018.
112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.